Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Scoring System LR-MDS and RBC transfusion–dependent anemia a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Garcia-Manero, Guillermo, Santini, Valeria, Almeida, Antonio, Platzbecker, Uwe, Jonasova, Anna, Silverman, Lewis R., Falantes, Jose, Reda, Gianluigi, Buccisano, Francesco, Fenaux, Pierre, Buckstein, Rena, Diez Campelo, Maria, Larsen, Stephen, Valcarcel, David, Vyas, Paresh, Giai, Valentina, Olíva, Esther Natalie, Shortt, Jake, Niederwieser, Dietger, Mittelman, Moshe, Fianchi, Luana, La Torre, Ignazia, Zhong, Jianhua, Laille, Eric, Lopes de Menezes, Daniel, Skikne, Barry, Beach, C. L., Giagounidis, Aristoteles
Format: Artigo
Idioma:Inglês
Publicat: Wolters Kluwer Health 2021
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8099416/
https://ncbi.nlm.nih.gov/pubmed/33764805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02619
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars